SE505316C2 - Användning av proteinet S-100b för framställning av läkemedel för nervceller - Google Patents

Användning av proteinet S-100b för framställning av läkemedel för nervceller

Info

Publication number
SE505316C2
SE505316C2 SE9503620A SE9503620A SE505316C2 SE 505316 C2 SE505316 C2 SE 505316C2 SE 9503620 A SE9503620 A SE 9503620A SE 9503620 A SE9503620 A SE 9503620A SE 505316 C2 SE505316 C2 SE 505316C2
Authority
SE
Sweden
Prior art keywords
nerve
protein
nerve cells
cells
axons
Prior art date
Application number
SE9503620A
Other languages
English (en)
Swedish (sv)
Other versions
SE505316C3 (sv
SE9503620D0 (sv
SE9503620L (sv
Inventor
Kenneth G Haglid
Original Assignee
Kenneth G Haglid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth G Haglid filed Critical Kenneth G Haglid
Priority to SE9503620A priority Critical patent/SE505316C2/sv
Publication of SE9503620D0 publication Critical patent/SE9503620D0/xx
Priority to EP96935706A priority patent/EP0952844A1/en
Priority to EE9800108A priority patent/EE9800108A/et
Priority to AU73523/96A priority patent/AU713332B2/en
Priority to NZ320721A priority patent/NZ320721A/en
Priority to JP9515742A priority patent/JPH11515003A/ja
Priority to CA002235278A priority patent/CA2235278A1/en
Priority to CZ981166A priority patent/CZ116698A3/cs
Priority to PCT/SE1996/001305 priority patent/WO1997014427A1/en
Priority to US09/051,589 priority patent/US5990080A/en
Publication of SE505316C3 publication Critical patent/SE505316C3/sv
Publication of SE9503620L publication Critical patent/SE9503620L/
Publication of SE505316C2 publication Critical patent/SE505316C2/sv
Priority to NO981719A priority patent/NO981719L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE9503620A 1995-10-17 1995-10-17 Användning av proteinet S-100b för framställning av läkemedel för nervceller SE505316C2 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9503620A SE505316C2 (sv) 1995-10-17 1995-10-17 Användning av proteinet S-100b för framställning av läkemedel för nervceller
US09/051,589 US5990080A (en) 1995-10-17 1996-10-15 Use of protein S-100-b in medicines containing the protein S-100b
EE9800108A EE9800108A (et) 1995-10-17 1996-10-15 Valgu S-100b kasutamine ravimites ja valku S-100b sisaldavad ravimid
EP96935706A EP0952844A1 (en) 1995-10-17 1996-10-15 USE OF PROTEIN S-100b IN MEDICINES AND MEDICINES CONTAINING THE PROTEIN S-100b
AU73523/96A AU713332B2 (en) 1995-10-17 1996-10-15 Use of protein S-100b in medicines and medicines containing the protein S-100-b
NZ320721A NZ320721A (en) 1995-10-17 1996-10-15 Use of the S-100b protein as a medicine to treat amyotrophic lateral sclerosis or multiple sclerosis
JP9515742A JPH11515003A (ja) 1995-10-17 1996-10-15 タンパク質Ｓ−１００ｂの薬剤への使用法、および該タンパク質Ｓ−１００ｂを含む薬剤
CA002235278A CA2235278A1 (en) 1995-10-17 1996-10-15 Use of protein s-100b in medicines and medicines containing the protein s-100b
CZ981166A CZ116698A3 (cs) 1995-10-17 1996-10-15 Použití proteinu S-100 v medicíně a léčivo obsahující protein S100-b
PCT/SE1996/001305 WO1997014427A1 (en) 1995-10-17 1996-10-15 USE OF PROTEIN S-100b IN MEDICINES AND MEDICINES CONTAINING THE PROTEIN S-100b
NO981719A NO981719L (no) 1995-10-17 1998-04-16 Anvendelse av protein S-100b i medisiner og medisiner inneholdende protein S-100b

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9503620A SE505316C2 (sv) 1995-10-17 1995-10-17 Användning av proteinet S-100b för framställning av läkemedel för nervceller

Publications (4)

Publication Number Publication Date
SE9503620D0 SE9503620D0 (sv) 1995-10-17
SE505316C3 SE505316C3 (sv) 1997-04-18
SE9503620L SE9503620L (sv) 1997-04-18
SE505316C2 true SE505316C2 (sv) 1997-08-04

Family

ID=20399846

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9503620A SE505316C2 (sv) 1995-10-17 1995-10-17 Användning av proteinet S-100b för framställning av läkemedel för nervceller

Country Status (11)

Country Link
US (1) US5990080A (et)
EP (1) EP0952844A1 (et)
JP (1) JPH11515003A (et)
AU (1) AU713332B2 (et)
CA (1) CA2235278A1 (et)
CZ (1) CZ116698A3 (et)
EE (1) EE9800108A (et)
NO (1) NO981719L (et)
NZ (1) NZ320721A (et)
SE (1) SE505316C2 (et)
WO (1) WO1997014427A1 (et)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258776B1 (en) * 1997-08-12 2001-07-10 Novartis Ag Calcium-regulated kinase
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20030108528A1 (en) * 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
DE19915485A1 (de) * 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz
WO2003047500A2 (en) 2001-12-06 2003-06-12 Yeda Research And Development Co. Ltd Vaccine and method for treatment of motor neurone diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9164591A (en) * 1990-12-14 1992-07-08 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons

Also Published As

Publication number Publication date
JPH11515003A (ja) 1999-12-21
EP0952844A1 (en) 1999-11-03
US5990080A (en) 1999-11-23
CA2235278A1 (en) 1997-04-24
AU7352396A (en) 1997-05-07
EE9800108A (et) 1998-10-15
CZ116698A3 (cs) 1998-09-16
WO1997014427A1 (en) 1997-04-24
NZ320721A (en) 2000-07-28
SE9503620D0 (sv) 1995-10-17
NO981719L (no) 1998-06-16
NO981719D0 (no) 1998-04-16
SE9503620L (sv) 1997-04-18
AU713332B2 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
DE69532996T2 (de) Peptidanaloge des menschlichen basischen myelinproteins
DE60029304T2 (de) Aktivierung von regulatorischen t zellen durch ein alpha-melanocyten stimulierendes hormon
Ren et al. Time window of intracisternal osteogenic protein-1 in enhancing functional recovery after stroke
CN108503690B (zh) 一种促进创伤后组织修复与再生的修复肽及其应用
AU2008334412A1 (en) Methods for inhibiting scarring
US11260101B2 (en) Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof
EA027343B1 (ru) Имплантируемые устройства медицинского назначения с повышенной иммунной толерантностью и способы изготовления и имплантирования
US6262024B1 (en) Neuron regulatory factor for promoting neuron survival
KR20190067219A (ko) 통증 예방, 경감 또는 치료에서의 신경 흥분성 상해 관련 폴리펩타이드의 용도
Christ et al. The application of gene therapy to the treatment of erectile dysfunction
DE60216458T2 (de) Verfahren zum auslösen einer anhaltenden immunreaktion
SE505316C2 (sv) Användning av proteinet S-100b för framställning av läkemedel för nervceller
SE505316C3 (sv) Användning av proteinet S-100b för framställning av läkemedel för nervceller
EP0756605B1 (de) Peptide als therapeutikum für autoimmunerkrankungen
CN115919804A (zh) 诱导Treg细胞分化的纳米载体系统及其在RA治疗中的应用
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物
CN110711244B (zh) 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
Thanos et al. Insulin-like growth factor-I promotes nerve regeneration through a nerve graft in an experimental model of facial paralysis
US5830857A (en) Method of treating epilepsy
RU2262945C1 (ru) Способ снижения массы тела в эксперименте на животных
RU2302237C2 (ru) Способ получения биологически активной фракции s-1-10, фармацевтическая композиция, снижающая тремор при паркинсонизме и судорожную активность при эпилепсии
CN101602793B (zh) 用于预防和/或治疗类风湿性关节炎的免疫调节多肽及其应用
JPH11507023A (ja) 血清免疫調節ポリペプチドおよびそれらの使用
RU2177325C1 (ru) Способ получения вещества, обладающего иммуностимулирующей активностью
JPH0680694A (ja) 創傷治癒に活性のあるポリペプチド・ポリマーイオン複合体

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 9503620-8

Format of ref document f/p: F